Taiyuan Market Supervision Administration Advances the Implementation of Unique Device Identification (UDI) for Medical Devices

Deep News
2025/10/17

On October 14, the Taiyuan Market Supervision Administration held a seminar on the implementation of Unique Device Identification (UDI) for medical devices in the city. The meeting aimed to implement the directives from the National Medical Products Administration and the Provincial Medical Products Administration, review the progress of UDI implementation across the city, and address challenges encountered during the process. Over 20 participants from the Administration’s medical device regulation department, relevant medical institutions, and medical device companies attended the meeting.

The meeting focused on interpreting the core value of UDI as a "digital identity card" for medical devices. It systematically conveyed the work requirements regarding UDI implementation from the National and Provincial Medical Products Administrations and reported on the results of a preliminary survey regarding UDI implementation in the city. Representatives from attending units reported on their respective UDI implementation progress and engaged in in-depth discussions about key issues encountered, such as the lack of unified coding standards, incompatible system interfaces, high data integration costs, poor integration with health insurance codes, and unfamiliarity of staff with operational procedures.

The meeting emphasized that all units should prioritize UDI implementation, concentrating efforts on key areas such as information system renovation, hardware and software upgrades, and data integration to drive the informatization of medical device traceability. It called for strengthened collaboration and coordination, establishing platforms for communication between medical institutions and companies. By synchronizing online and offline interactions and regularly sharing information, the aim is to collaboratively address and efficiently resolve challenges. Furthermore, it urged enhanced supervision and proactive service to orderly promote the implementation of precise traceability regulatory measures throughout the entire lifecycle of medical devices, ensuring the safety of devices used by the public.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10